Clinical trial data shows that burping rates vary by drug and dose: Ozempic injection (semaglutide): Burping reported in 3% of patients at the 0.5 mg dose and 1% of patients at the 1 mg dose Wegovy injection (semaglutide): Burping reported in 7% of adults at the 2.4 mg dose Mounjaro and Zepbound (tirzepatide): Burping reported in 25% of patients across doses (Source: Drugs.com) These numbers likely underestimate real-world prevalence, as sulfur burps are often underreported in clinical trials or described under broader terms like belching or eructation. Some patients avoid mentioning it to their doctors out of embarrassment, as well
According to primary trials in T2DM, tirzepatide significantly reduces clinical outcomes like body weight, glycated hemoglobin (HbA1c), lipid profiles, and glucose-adjusted glucagon secretion compared to typical glucagon-like peptide1 receptor agonists (GLP1RAs) [1, 2]
In January 2025, Novo Nordisk stated that the United States Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease progression, kidney failure (end-stage renal disease), and cardiovascular disease-related death in individuals with type 2 diabetes and chronic kidney disease (CKD)
Recommended dose:Take 1 capsule, 2 times a day preferably with lukewarm milk
An overall process flow and an elution profile of oIGF-1 from reversed-phase HPLC is shown in Figure 1
(July 21, 2023)
